# Sionna Therapeutics Inc. (SION) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $7.18, market value $324 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Sionna Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 1.2×**. The shares trade at 1.2× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -23.5%** (5-yr avg -4.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -24.5%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): 88.2%**. Earnings per share rose 88.2%.

## Financial health
- **Current ratio: 20.61** (quick 20.61). Current assets cover the next year's liabilities 20.61 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Sionna Therapeutics Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): -68.9%** (YTD -82.5%, 3-mo -79.7%). The shares are down 68.9% over twelve months including dividends.
- **From 52-week high: -86.9%** (79.1% above the low). Trading 87% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 29**. An RSI of 29 is oversold; bounces are common, but oversold can stay oversold in a real decline.
- **Beta (1 yr): 1.01** (volatility 124%). Beta of 1.01 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SION · Page: https://foliofundamentals.com/stocks/sion

Not investment advice.